Get the Stockscreener App
10.72
1.74%
-0.19
After Hours:
10.73
0.010
+0.09%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $10.72, with a volume of 7.39M.
It is down -1.74% in the last 24 hours and up +7.96% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$10.91
Open:
$10.83
24h Volume:
7.39M
Relative Volume:
0.79
Market Cap:
$12.50B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.3817
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+5.93%
1M Performance:
+7.96%
6M Performance:
+27.32%
1Y Performance:
-15.06%
1-Day Range:
$10.66
$10.90
1-Week Range:
$9.985
$11.28
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.72 | 12.57B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
What does recent volatility data suggest for Viatris Inc.Earnings Overview Summary & Weekly Top Gainers Trade List - newser.com
Why Viatris Inc. stock could be next big winnerQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Can Viatris Inc. (VIA) stock surprise markets with earningsJuly 2025 Opening Moves & Safe Entry Zone Tips - newser.com
Should I hold or sell Viatris Inc. stock in 2025Weekly Earnings Recap & AI Enhanced Market Trend Forecasts - Fundação Cultural do Pará
Is it time to cut losses on Viatris Inc.2025 Price Momentum & Growth Oriented Trade Recommendations - newser.com
What technical charts say about Viatris Inc. stockGlobal Markets & Expert Approved Trade Ideas - newser.com
Viatris (VTRS): Assessing Valuation After Raised 2025 Guidance and Strong Earnings Signals - Yahoo Finance
Viatris (VTRS) Is Up 7.9% After Boosting 2025 Revenue Outlook and Reaffirming Dividend - simplywall.st
Is now a turning point for Viatris Inc.2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
What is the fair value estimate for Viatris Inc. (VIA) stock in 2025Market Performance Report & Reliable Breakout Forecasts - newser.com
Will Viatris Inc. (VIA) stock benefit from commodity supercycleQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
How Recent Developments Are Rewriting the Story for Viatris - Yahoo Finance
Will Viatris Inc. stock go up soonJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
Using AI based signals to follow Viatris Inc.2025 Big Picture & Technical Confirmation Alerts - newser.com
Viatris Recognized as One of the Fortune World's Best Workplaces in 2025 - Finviz
Viatris (NASDAQ: VTRS) among 25 on Fortune World's Best Workplaces, from 9M+ responses - Stock Titan
Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS) - Barchart.com
Is Viatris Inc. (VIA) stock overpriced at current multiples2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
What dividend safety score for Viatris Inc. stockJuly 2025 Drop Watch & Reliable Price Breakout Alerts - newser.com
Viatris (VTRS) Jumps 10% on Reaffirmed Growth Targets - MSN
Viatris Inc. stock rises Tuesday, outperforms market - MSN
Evaluating Viatris (VTRS) Valuation After Strong Q3 Results and Upbeat 2025 Guidance - simplywall.st
What drives Viatris Inc VIA stock priceChart Pattern Recognition & Small Budget Investment Tips - earlytimes.in
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know - The Globe and Mail
U.S. Markets Finished Mixed Tuesday As Viatris Led, CoreWeave Lagged - Barron's
Viatris at UBS Global Healthcare Conference: Strategic Growth Initiatives - Investing.com India
Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics - Yahoo Finance
Will Viatris Inc. stock return to pre crisis levelsJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
Type 2 Diabetes MarketSee Which Drugs Are Leading in 2025Novo - openPR.com
Viatris’ Indore Plant Remediation ‘Largely Complete’ As FDA Re-Inspection Looms - Citeline News & Insights
Is Viatris Inc. stock a good choice for value investors2025 Major Catalysts & Accurate Technical Buy Alerts - newser.com
Will Viatris Inc. stock recover faster than peers2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
Viatris Inc. stock outlook for YEARPortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
4.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):